Good day to all. Listened to the last (23/3/202
Post# of 148169
(Total Views: 759)
Posted On: 03/24/2021 8:56:26 AM
Good day to all.
Listened to the last (23/3/2021) conference with attention.
The Oncology part was music to my ears (as was in the last conference as well).
I invested initially due to HIV (I really liked the SAE-free part of our drug) and then, one day, in researching other investment opportunities, and reading about PD-L1, I came across CCR5 once more.
I started consequently to buy CYDY in quantities beyond my money-management guidelines.
I broke my long-held beliefs and don't regret it.
Oncology is the BIG prize and Kelly's comments are correct. Only ONE cancer indication we can address and we are golden.
If somebody needs comfort and sleep sweetly I suggest you keep a paper by your bed-table and read a little before going to sleep.
For example Jiao's paper (there are quite a few others) " Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy "
https://breast-cancer-research.biomedcentral....21-01391-1
The above is only for BC. If the moa extends to other types ... (which it does).
How much are our shares worth ???
That is why I keep mine and am not selling a single one.
COVID?? sure, as means to fund Cancer trials !!!.
In this order of ideas, imo, the next BIG SP catalyzer will be our BTD for cancer. This will catapult us (should) to several multiples of current price
The market is around 22 Billion (US alone). You put any market share (once we are approved) there and you see what I mean. I am doing a "three fingers" here.
We have good days ahead.
Listened to the last (23/3/2021) conference with attention.
The Oncology part was music to my ears (as was in the last conference as well).
I invested initially due to HIV (I really liked the SAE-free part of our drug) and then, one day, in researching other investment opportunities, and reading about PD-L1, I came across CCR5 once more.
I started consequently to buy CYDY in quantities beyond my money-management guidelines.
I broke my long-held beliefs and don't regret it.
Oncology is the BIG prize and Kelly's comments are correct. Only ONE cancer indication we can address and we are golden.
If somebody needs comfort and sleep sweetly I suggest you keep a paper by your bed-table and read a little before going to sleep.
For example Jiao's paper (there are quite a few others) " Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy "
https://breast-cancer-research.biomedcentral....21-01391-1
Quote:
Results
Herein, leronlimab was shown to bind CCR5 in multiple breast cancer cell lines. Binding of leronlimab to CCR5 reduced ligand-induced Ca+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration. Leronlimab enhanced the BCa cell killing of the BCa chemotherapy reagent, doxorubicin. In xenografts conducted with Nu/Nu mice, leronlimab reduced lung metastasis of the TNBC cell line, MB-MDA-231, by > 98% at 6 weeks. Treatment with leronlimab reduced the metastatic tumor burden of established TNBC lung metastasis.
Quote:
In the analysis of > 2200 breast cancer patients, > 50% of patient’s tumors were CCR5+. and > 95% of triple-negative breast cancer (TNBC) were CCR5+. Several characteristics of CCR5 suggest the receptor may be important in human breast cancer. CCR5 receptor levels correlate with poor prognosis in breast cancer. CCR5 expression correlates well with increased tumor heterogeneity in breast cancer. Upon transformation of breast epithelial cells, the increased expression of CCR5 results in increased motility and homing behavior to metastatic sites. Furthermore, CCR5+ breast cancer epithelial cells have both enhanced tumor-initiating capacity and form mammospheres with greater efficiency in mice, a feature of cancer stem cells. Finally, ectopic CCR5 expression within cancer epithelial cells is sufficient to drive cancer cell metastasis.
The above is only for BC. If the moa extends to other types ... (which it does).
How much are our shares worth ???
That is why I keep mine and am not selling a single one.
COVID?? sure, as means to fund Cancer trials !!!.
In this order of ideas, imo, the next BIG SP catalyzer will be our BTD for cancer. This will catapult us (should) to several multiples of current price
The market is around 22 Billion (US alone). You put any market share (once we are approved) there and you see what I mean. I am doing a "three fingers" here.
We have good days ahead.
(28)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼